Calidi Biotherapeutics (CLDI) News Today $6.18 -1.07 (-14.76%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$6.48 +0.30 (+4.85%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Calidi Biotherapeutics Inc trading resumesAugust 5 at 3:23 PM | msn.comCalidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025July 25, 2025 | globenewswire.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24July 22, 2025 | finance.yahoo.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24July 22, 2025 | globenewswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million ...July 11, 2025 | morningstar.comMCalidi Biotherapeutics secures $4.6 million through warrant exerciseJuly 11, 2025 | investing.comCalidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer TreatmentJuly 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross ProceedsJuly 9, 2025 | globenewswire.comCalidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer TreatmentJuly 8, 2025 | globenewswire.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEOJune 27, 2025 | finanznachrichten.deCalidi Biotherapeutics Announces Shareholder Letter from CEOJune 27, 2025 | globenewswire.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 16, 2025 | finanznachrichten.deCalidi Biotherapeutics Strengthens Leadership Team and Advances Antitumor Virotherapy Platform with New CEO and Chief Medical Officer AppointmentsMay 16, 2025 | nasdaq.comCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 15, 2025 | tmcnet.comCalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual MeetingApril 28, 2025 | finance.yahoo.comCalidi reports inducement grant unders NYSE American guideApril 26, 2025 | markets.businessinsider.comCalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711April 25, 2025 | globenewswire.comCalidi appoints Eric Poma as CEO, directorApril 24, 2025 | markets.businessinsider.comCalidi announces FDA clearance of IND application for CLD-201April 18, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsApril 17, 2025 | markets.businessinsider.comCalidi appoints Guy Travis Clifton as CMO, Consultant, AdvisorApril 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and AdvisorApril 10, 2025 | finance.yahoo.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational HighlightsMarch 31, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 31, 2025 | globenewswire.comCalidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent GliomaMarch 28, 2025 | nasdaq.comCalidi prices 3.33M shares at 65c in registered direct offeringMarch 28, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 28, 2025 | globenewswire.comCalidi, City of Hope provide update on Phase 1 trial with CLD-101March 27, 2025 | markets.businessinsider.comIBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | finance.yahoo.comCalidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | theglobeandmail.comCalidi announces ability to deliver transient gene therapy to tumorsMarch 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic PlatformMarch 10, 2025 | globenewswire.comCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 28, 2025 | finanznachrichten.deCalidi commences recruitment for multiple dose CLD-101 trialFebruary 24, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University HospitalFebruary 24, 2025 | globenewswire.comCalidi Biotherapeutics expands stock offering capacityFebruary 5, 2025 | msn.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5January 30, 2025 | markets.businessinsider.comCLDI Stock Plummets to 52-Week Low at $0.6 Amid Market TurbulenceJanuary 30, 2025 | msn.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5January 29, 2025 | globenewswire.comCalidi announces termination of standby equity purchase agreementJanuary 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase AgreementJanuary 28, 2025 | globenewswire.comCLDI stock touches 52-week low at $0.73 amid market challengesJanuary 22, 2025 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public OfferingJanuary 13, 2025 | theglobeandmail.comCalidi to present new data on systemic virotherapy RTNova platformJanuary 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025January 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Prices Offering Of 5 Mln Shares At $0.85/Share, Stock FallsJanuary 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics slumps 29%, prices $4.25M stock offeringJanuary 10, 2025 | msn.comCalidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi announces common stock offering, no amount givenJanuary 9, 2025 | markets.businessinsider.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼-0.750.42▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼31▲CLDI Articles Average Week Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Metagenomi News Today eXoZymes News Today Vaxart News Today ESSA Pharma News Today Alto Neuroscience News Today BeyondSpring News Today Elutia News Today Surrozen News Today ImmunoPrecise Antibodies News Today Cabaletta Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CLDI) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts